Are you looking for the next big stock to add to your portfolio? Look no further than Hims & Hers (HIMS), a digital consumer-facing health-care company that is on the verge of breaking out to a new all-time high. At Extreme Investor Network, we believe that HIMS is a stock worth watching closely.
HIMS may have initially struggled after coming to market via a SPAC run by Howard Marks’ Oaktree Capital Management in October 2020, but the stock has since regained its footing and is now heading back towards all-time highs. With the recent announcement of a weight loss injection product to compete with industry giants like Eli Lilly and Novo Nordisk, HIMS is positioning itself as a major player in the health-care industry.
What sets HIMS apart is its unique business model that includes over one million subscribers using a wide variety of treatments, from mental health services to dermatology cosmetics. Additionally, HIMS is leveraging an FDA loophole to sell its weight loss injection at an 85% discount to its competitors, making it an attractive option for consumers.
We believe that HIMS has the potential to deliver strong earnings and guidance in its upcoming August 5th report, which could propel the stock to new highs. With a valuation that still remains reasonable compared to its explosive growth potential, HIMS is a stock that should be on every investor’s radar.
Stay tuned to Extreme Investor Network for the latest updates and insights on HIMS and other promising investment opportunities. Remember, before making any financial decisions, always consult with your own financial advisor. Happy investing!